{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-102178","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2026-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.269217+00:00","generated_at":"2026-05-15T14:58:38.778093+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Relay Therapeutics adopts exclusive federal forum for securities claims","bullets":["Board approved second amended and restated bylaws effective March 6, 2026.","New exclusive forum provision requires securities law claims to be brought in federal district courts unless company consents otherwise.","Amendment covers claims under Securities Act of 1933 and Exchange Act of 1934.","No other material changes to bylaws were disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-102178","json":"https://secwatch.observer/filing/0001193125-26-102178.json","markdown":"https://secwatch.observer/filing/0001193125-26-102178.md","text":"https://secwatch.observer/filing/0001193125-26-102178.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526102178/0001193125-26-102178-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526102178/rlay-20260306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T14:58:38.778093+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d503c952711e1587dab27bb19f1eb3018e466c2b","claim":"Relay Therapeutics, Inc.: Amended and restated bylaws to designate federal district courts as exclusive forum for Securities Act and Exchange Act claims (effective 2026-03-06).","evidence_excerpt":"On March 6, 2026, the Board of Directors (the “Board”) of Relay Therapeutics, Inc. (the “Company”) approved an amendment and restatement of the Company’s amended and restated bylaws (the “A&R Bylaws”), effective immediately, to designate the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526102178/0001193125-26-102178-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2026-03-06"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}